Brind.

CASI Pharmaceuticals, a company based in the United States, has David Cory as its CEO, and Ingrid Choong is listed as a company contact.

8 reports, 1 independent Updated Aug 14
Gone quiet
Reports
8
Developments
3
Repetition
62%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

CASI Pharmaceuticals, a company based in the United States, has David Cory as its CEO, and Ingrid Choong is listed as a company contact.

Who's involved

What this event is mainly about
CASI Pharmaceuticals (United States)David CoryIngrid Choong

How it developed

Newest first. Tap a step to see who reported it.
  1. CASI Pharmaceuticals appoints David Cory as CEO and lists Ingrid Choong as a company contact.1 source
  2. FDA cleared CASI's IND application for CID-103.1 source
  3. FDA cleared IND application for CID-103, a development concerning CASI Pharmaceuticals.1 source

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • ACCESS NewswireCASI Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference SOUTH SAN FRANCISCO, CA / ACCESS Newswire / September 3, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a
  • ACCESS NewswireCASI Pharmaceuticals Announces Second Quarter 2025 Business and Financial Results SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / August 29, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a cli
  • ACCESS NewswireCASI Pharmaceuticals to Participate at Cantor Global Healthcare Conference 2025 SAN FRANCISCO, CA / ACCESS Newswire / August 28, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biop
  • ACCESS NewswireCASI Pharmaceuticals Announces FDA Clearance of IND Application for CID-103 in Renal Allograft Antibody-Mediated Rejection (AMR) CID-103 is a potential best-in-class, anti-CD38 monoclonal antibody; b
  • ACCESS NewswireCASI Pharmaceuticals Appoints David Cory as Chief Executive Officer to Lead U.S. Company Focused on Clinical Development of CID-103, a Potential Best in Class Anti-CD38 Program -- David Cory is an in
3 more outlets ran the same wire story